Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open label phase 1 study assessing the effect of paroxetine, a strong CYP2D6 inhibitor, on the formation and elimination of two metabolites in healthy subjects

Next Previous
Trial Profile

Open label phase 1 study assessing the effect of paroxetine, a strong CYP2D6 inhibitor, on the formation and elimination of two metabolites in healthy subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ulotaront (Primary) ; Paroxetine
  • Indications Generalised anxiety disorder; Major depressive disorder; Mental disorders; Psychotic disorders; Schizophrenia
  • Focus Pharmacokinetics

Most Recent Events

  • 06 Nov 2023 New trial record
  • 12 Sep 2023 Results assessing effect of paroxetine, a strong CYP2D6 inhibitor, on the formation and elimination of these two metabolites in healthy subjectspresented at the 2023 American College of Clinical Pharmacology Annual Meeting

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top